Table 2 Subgroup analysis of overall cancer risk in the combined IgG4-RD population
From: The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
Subgroup | No. of studies | SIR (95% CI) | Heterogeneity analysis | |
|---|---|---|---|---|
I2 | p value | |||
Study quality | Â | Â | Â | Â |
NOS<6 | 4 | 2.05 (1.14–3.68) | 62.7% | P<0.05 |
NOS≥6 | 6 | 3.06 (1.72–5.45) | 80.3% | P<0.05 |
Geographic region | Â | Â | Â | Â |
Asia | 7 | 2.13 (1.40–3.24) | 72.2% | P<0.05 |
Non-Asia | 3 | 4.64 (1.64–13.13) | 74.5% | P<0.05 |
Follow-up time, years | Â | Â | Â | Â |
 <5 | 6 | 2.69 (1.56–4.64) | 72.7% | P<0.05 |
 ≥5 | 3 | 1.78 (1.08–2.94) | 64.6% | P>0.05 |